The Breast Cancer Market Is Set to Grow to More Than $15 Billion by 2022

Approval of Premium-Priced Novel Therapies and Continued Uptake of Recent Market Entrants Will Help Fuel 5 Percent Annual Growth in the Breast Cancer Market, According to Findings from Decision Resources

Aug 22, 2013, 11:30 ET from Decision Resources

BURLINGTON, Mass., Aug. 22, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the uptake of premium-priced agents will fuel 5 percent annual growth in the breast cancer market, with sales reaching more than $15 billion in 2022 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan. The uptake of Roche/Genentech/Chugai's Perjeta and Kadcyla for HER2-positive disease, as well as the continued use of Novartis's Afinitor and launch of Pfizer's palbociclib for hormone-receptor positive disease will contribute to growth in the breast cancer market through 2022, off-setting sales erosion of key current therapies such as Roche/Genentech/Chugai's Herceptin that are due to lose patent protection over the next decade.

(Logo: )

The Pharmacor Breast Cancer advisory service also finds that sales for HER2-positive breast cancer dominate the current market, accounting for 41 percent of major market sales in 2012 and will continue to do so through 2022, owing to the availability of several targeted agents specifically approved for this market segment. 

The findings also reveal strong sales growth from agents positioned to treat hormone receptor-positive, HER2-negative breast cancer. Afinitor's launch in this indication in 2011 as well as palbociclib's anticipated approval will boost sales from this large market segment.

"New market entrants are set to change the way many breast cancer patients are treated by 2022," said Decision Resources Principal Analyst Amy Duval. "The evolving HER2-positive market segment will see the incorporation of Perjeta and Kadcyla, diversifying the treatment options available for these patients at different stages of disease. Targeted therapies Afinitor and palbociclib will impact the way many advanced hormone receptor-positive patients are managed."

About Decision Resources
Decision Resources ( is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

SOURCE Decision Resources